feisty
HRT for menopause, or hormone replacement therapy, has spent two decades caught in a risk conversation that the evidence no longer fully supports. For most healthy women under 60 who start treatment within 10 years of their last period, the benefits of HRT are well established, and the risks are lower than they were once thought to be. Understanding what it does, how it's delivered, and who it suits best is the starting point for making a real decision, not a fear-based one.
What HRT actually does in the body
Menopause causes estrogen levels to drop sharply. That drop is what drives most of the symptoms: hot flushes, night sweats, vaginal dryness, disrupted sleep, joint pain, and mood changes. HRT replaces that lost estrogen, which is why it works faster and more reliably than any other intervention for vasomotor symptoms like flushes and sweats.
Estrogen also protects bone density. After menopause, bone loss accelerates, and HRT slows that process. Studies published in the past decade confirm it reduces fracture risk in postmenopausal women, a benefit that continues for as long as therapy continues. For women who carry early osteoporosis risk, that's a serious clinical reason to consider it, not just comfort management.
Women who still have a uterus also need progestogen alongside estrogen. Estrogen alone thickens the uterine lining; progestogen counteracts that effect and reduces the risk of endometrial cancer. Women who have had a hysterectomy can take estrogen-only therapy.
Types of HRT and how they're delivered
HRT comes in several forms, and the delivery method changes the risk profile.
- Transdermal estrogen (patches, gels, sprays): absorbed through the skin, bypasses the liver, and does not carry the same blood clot risk as oral estrogen. This is the form most guidelines now recommend as the default for healthy women.
- Oral estrogen: the pill form, effective but associated with a small increased risk of blood clots, particularly in women with existing risk factors. Still appropriate for many women with no clotting history.
- Vaginal estrogen: a low-dose local treatment for vaginal dryness, urinary symptoms, and recurring UTIs. It does not significantly raise systemic estrogen levels. Women can use vaginal estrogen in addition to systemic HRT or instead of it if their main symptoms are local.
- Progestogen options: micronised progesterone (body-identical, derived from yams) is the form with the best safety profile for breast tissue. Synthetic progestogens vary in their side-effect profiles.
The breast cancer question, answered plainly
The 2002 Women's Health Initiative study is what caused HRT prescriptions to collapse. It showed a small increased risk of breast cancer, particularly with combined estrogen-progestogen therapy. That finding still stands for some types of HRT, but the picture is more complicated now.
Estrogen-only HRT (for women without a uterus) does not appear to raise breast cancer risk. Combined HRT with micronised progesterone carries a lower breast cancer risk than combined HRT with synthetic progestogens. The absolute risk increase for most women taking combined HRT for under 5 years is small, comparable to the risk associated with drinking one alcoholic drink per day or being overweight.
For women with a personal history of breast cancer, HRT is generally not recommended. For everyone else, the decision depends on symptom severity, individual risk factors, and personal preference. It's a conversation, not a blanket prohibition.
Who HRT is and isn't right for
Most healthy women experiencing moderate to severe menopause symptoms are candidates. The strongest evidence sits with women aged 50 to 59, or within 10 years of menopause. Starting HRT during this window is called the "timing hypothesis" or "window of opportunity," and the evidence consistently shows better cardiovascular outcomes when therapy begins here rather than later.
HRT is not recommended for women with a current or recent history of breast cancer, blood clots, untreated high blood pressure, or active liver disease. Women with a history of cardiovascular disease need individual assessment. These are reasons to discuss carefully with a doctor, not automatic disqualifiers for every type or delivery method.
For women in perimenopause, HRT can also help manage the erratic hormonal swings that arrive before periods stop entirely. The approach is the same; the conversation with a GP just needs to account for where in the transition you are.
What HRT does not do
HRT relieves symptoms. It is not a weight loss tool. Body composition changes during menopause are driven largely by age-related muscle loss and metabolic shifts, not estrogen deficiency alone. HRT can help preserve muscle mass and reduce central fat gain, but it won't reverse weight already gained without other changes. For that part of the picture, menopause treatments like resistance training and protein-focused eating do the heavier lifting.
HRT also does not prevent dementia. Earlier observational studies suggested a protective effect, but randomised trials have not confirmed this consistently. Research continues, but it's not a reason to start or continue HRT on its own.
How to have a useful conversation with your GP
Many women still report being dismissed or given outdated advice when they raise HRT. Going in prepared helps. A few specifics worth raising:
- Ask whether transdermal estrogen is appropriate for you, given it avoids the clot risk of oral forms.
- Ask about micronised progesterone specifically, not just "progestogen," as it has a better tolerability and safety profile than synthetic versions.
- Ask for a structured review at 3 months to assess whether the dose is working, rather than waiting a full year.
- If your GP is uncertain or dismissive, the Australasian Menopause Society maintains a directory of menopause-trained clinicians.
The conversation doesn't need to be adversarial. But knowing the current evidence means you can ask specific questions rather than accepting a general "let's wait and see."
Body-identical vs bioidentical HRT: what the terms actually mean
These two terms cause real confusion. Body-identical HRT refers to regulated, pharmacy-dispensed hormones (like estradiol and micronised progesterone) that are chemically identical to those the body produces. These are prescription medicines with evidence behind them.
Bioidentical HRT is a marketing term used by compounding pharmacies. It describes custom-mixed hormone preparations that are not subject to the same regulatory scrutiny, quality control, or clinical trial data as regulated products. Most menopause specialists do not recommend compounded bioidenticals over regulated body-identical options because the evidence base is weaker and the dosing is less reliable. This distinction matters when you see products marketed as "natural" alternatives.
How long to stay on HRT
There is no fixed upper limit. The old advice to stop at 5 years has been largely abandoned. Current guidance from the British Menopause Society and the Australasian Menopause Society says that for most women without contraindications, HRT can continue as long as the benefits outweigh the risks, and that decision should be reviewed annually with a clinician. Some women find symptoms return sharply when they stop; others taper off without difficulty. Both are normal.
The annual review isn't just a formality. Blood pressure, cardiovascular health, and mammography results all factor into whether the calculus still makes sense. It's a live assessment, not a set-and-forget prescription.